NASDAQ: SPPI DEADLINE REMINDER: Berger Montague Reminds Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors of Important Class Action Lawsuit Deadline

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares during the specified class period [1][2] Group 1: Legal Action - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who purchased Spectrum securities during the class period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Group 2: Company Background - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] - The company's shares were delisted following its merger with Assertio Holdings, Inc. [3]